In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changing the Tires on a Moving Car: Restructured Alliances

Executive Summary

A look at deals in which the partners, through renegotiation, were able to navigate around an unforeseen, potentially deal-killing (or partner-killing) event.

You may also be interested in...



Exelixis/GSK: Using Project Financing to Accelerate R&D

Productivity in biotech is a better problem to have than its opposite-but paying the higher-than-expected development costs makes it still a problem. Thanks to a variety of new project financing sources, and a particularly clever approach to amending its alliance with GlaxoSmithKline, Exelixis is fact trying to turn research productivity into a source of non-dilutive capital.

Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials

Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.

With CBD Products Unlawful, FDA Enforcement Policy Guidance Has No Economic Significance

As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel